September 29, 2010 — In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital, Boca Raton, Fla., showed that positron emission mammography (PEM) and breast magnetic resonance imaging (MRI) had a comparably high ability to detect cancerous lesions.

The prospective study enrolled 182 women with recent biopsy-proven primary breast cancer. It also found that PEM was not impacted by menopausal status, breast density or hormone replacement therapy, making PEM a valuable alternative.

PEM scanners are high-resolution breast positron emission tomography (PET) systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians to make the optimal cancer care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.” PEM is different from X-ray mammography in that it is currently not used as a screening modality, rather is deployed to confirm extent of disease in a patient already diagnosed with a primary breast cancer.

“We were very pleased to find that PEM and MRI had comparable ability to detect cancerous lesions regardless of type or severity of the tumor,” said Kathy Schilling, M.D., lead author on the study. “In addition, the data showed that PEM is a fantastic alternative for women with dense breasts or where timing of an MRI due to menstrual cycle is challenging. The next step is to understand how PEM and MRI compare when differentiating between benign and malignant suspicious lesions.”

Results from a separate NIH-sponsored clinical study (NIH Grant 5R44CA103102), recently presented at the 2010 Society of Nuclear Medicine Annual Meeting, comparing PEM and breast MRI help answer Dr. Schilling’s question. The multi-site study of hundreds of women with newly diagnosed breast cancer shows that PEM demonstrated a 6 percent improvement in specificity, ability to differentiate between malignant and benign lesions, suggesting that PEM may reduce unnecessary biopsies. These results are particularly significant for women who cannot tolerate an MRI exam and require an alternate imaging tool. The study is slated for publication in the December issue of the journal Radiology.

For more information: naviscan.com


Related Content

News | Artificial Intelligence

June 15, 2026 — HOPPR recently announced that HOPPR AI Foundry is now available in AWS Marketplace. The availability ...

Time June 19, 2026
arrow
News | Radiology Imaging

June 15, 2026 — Lead Glass Pro, a supplier of radiation shielding products, has expanded its turnkey installation ...

Time June 18, 2026
arrow
Feature | Magnetic Resonance Imaging (MRI)

The majority of MRI scanners require about 1,500 liters of liquid helium to operate, but geopolitical unrest is putting ...

Time June 17, 2026
arrow
News | Digital Pathology

June 15, 2026 — Leica Biosystems is expanding the availability of its Aperio GT Elite digital scanner into the EMEA ...

Time June 15, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

June 9, 2026 — An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for ...

Time June 15, 2026
arrow
News | Radiology Business

June 9, 2026 — Bayer has appointed Dr. Jost Reinhard president of the Radiology business within Bayer’s Pharmaceuticals ...

Time June 12, 2026
arrow
News | PET-MRI

June 10, 2026 — UTHealth Houston has launched a state-of-the-art PET/MRI imaging service, bringing together two advanced ...

Time June 12, 2026
arrow
News | Enterprise Imaging

June 9, 2026 — GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging ...

Time June 09, 2026
arrow
News | Innovative Hospitals

May 27, 2026 — Nearly two years after announcing plans for a “real-world” academic-industrial collaboration, GE ...

Time June 03, 2026
arrow
News | Nuclear Imaging

June 1, 2026 — At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE HealthCare will ...

Time June 02, 2026
arrow
Subscribe Now